Compare Rigetti Computing Inc (RGTI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rigetti Computing Inc vs Tango Therapeutics Inc. — how do they compare? Rigetti Computing Inc trades at $11.39 (market cap $4.27B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Rigetti Computing Inc and Tango Therapeutics Inc. are close in size by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rigetti Computing Inc for 36 Days and Tango Therapeutics Inc. for 0 Days on average.
| RGTI | TNGX | |
|---|---|---|
Market Cap | $4.27B | $3.75B |
Volume | 14,966,259 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $56.34 | $32.90 |
52-Week Low | $11.68 | $7.50 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $3.88B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGTI trades at $12.78, down 3.55% today, with bearish technical signals but strong analyst support. The company shows negative profitability with a -1,787.4% net income margin despite recent earnings beats. Revenue growth from $7M to $13M (2025-2026) is overshadowed by escalating losses. Cash flow remains negative, though financing activities provide liquidity. Recent quantum computing sector news highlights competitive positioning and technological advancements.
Outlook remains speculative with high execution risk; Wall Street consensus is bullish (85.7% buy ratings) with a $21.67 price target implying 70% upside. Key risks include sustained losses, intense competition, and reliance on future quantum technology adoption. The stock offers high-risk growth potential for investors comfortable with speculative emerging technology plays.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
